BRCA1 and breast cancer: The PARP inhibitors olaparib and talazoparib were recently FDA approved for use as monotherapy in patients with metastatic germline BRCA1/2-mutated breast cancer based on significant improvement in progression-free survival compared to chemotherapy31.